- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07270575
Imeytyvät tukirakenteet everolimuus-eluutiolla infrapoplietaalisten valtimoiden sairauden hoitoon kroonisesta raaja-uhkaavasta iskemiasta kärsivillä potilailla (RESCUE)
Resorboituvat tukirakenteet everolimuus-eluuviolla polvialavaltimotautien hoitoon kroonisessa raajan uhkaavassa iskemiassa sairastavilla potilailla
RESCUE is a Europe-wide study that will follow 400 people with critical limb-threatening ischemia (CLTI). It aims to see how well Esprit BTK™ Everolimus Eluting Resorbable Scaffolds work in real-life medical settings. The study focuses on people who have heavily calcified arteries in the infrapopliteal areas of the leg.
These drug-eluting resorbable scaffolds release a medication that helps prevent the inner wall of the blood vessel from thickening after injury or surgery. This can reduce the chance of the artery becoming blocked again (a problem called restenosis), while also giving temporary structural support to the vessel. Over time, the scaffold naturally dissolves in the body, which may lower the long-term risks associated with permanent metal stents.
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Claire Poulet, PhD
- Puhelinnumero: +41 79 385 16 78
- Sähköposti: oracue@cirse.org
Tutki yhteystietojen varmuuskopiointi
- Nimi: Dhwani S. Korde, PhD
- Puhelinnumero: +4367762942469
- Sähköposti: oracue@cirse.org
Opiskelupaikat
-
-
-
Hull, Yhdistynyt kuningaskunta, HU3 2JZ
- Rekrytointi
- Hull University Teaching Hospitals NHS Trust
-
Päätutkija:
- Raghu Lakshminarayan, Dr
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Näytteenottomenetelmä
Tutkimusväestö
Adult CLTI patients treated with the Esprit BTK everolimus-eluting resorbable scaffold following adequate vessel preparation for infrapopliteal artery disease.
Kuvaus
Inclusion Criteria:
- Rutherford classification category ≥4;
- Treatment of infrapopliteal lesions with the Esprit BTK everolimus eluting resorbable scaffold system following adequate vessel preparation;
- Calcification of target lesions must be visible on fluoroscopy or CT-angiography;
- Patients competent and willing to provide informed consent.
Exclusion Criteria:
- Minors and other vulnerable populations who may not be able to give informed consent freely or for whom participation is not essential to the study (incapacitated and unconscious individuals, persons deprived of liberty, pregnant and breastfeeding women, etc.);
- Inadequate inflow (>30% stenosis) following optimization;
- Insufficient direct outflow (less than 1 run-off vessel);
- Endovascular procedure(s) on the treatment site within 4 weeks before index procedure;
- Patients planned to receive an above ankle amputation of the target limb;
- Patients enrolled in ORACLE (ClinicalTrials.gov ID NCT07270562).
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Havaintomallit: COHORT
- Aikanäkymät: PROSPECTIVE
Kohortit ja interventiot
Ryhmä/Kohortti |
Interventio / Hoito |
|---|---|
|
Adult CLTI patients with infrapopliteal calcified lesions
Adult CLTI patients planned to receive the Esprit BTK™ resorbable scaffold following pre-dilatation with angioplasty balloon. |
The Esprit BTK™ is a bioresorbable vascular scaffold designed for arteries below the knee. It provides temporary support to keep the vessel open while releasing everolimus-an antiproliferative drug that helps prevent excessive tissue growth and reduces the risk of restenosis. As the scaffold delivers the medication, it gradually dissolves, potentially lowering long-term risks associated with permanent stents.
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Number of lesions free from Clinically-Driven Target Lesion Revascularization (CD-TLR)
Aikaikkuna: 12 months
|
Defined as freedom from any endovascular re-intervention to the target lesion (± 10 mm) or surgical bypass performed because of restenosis or occlusion of the target lesion. |
12 months
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
CD-TLR-free survival per target lesion
Aikaikkuna: Until the end of the follow-up period of 3 years
|
Defined as the time between first index procedure and any endovascular re-intervention to the target lesion (± 10 mm) or surgical bypass performed because of restenosis or occlusion of the target lesion. |
Until the end of the follow-up period of 3 years
|
|
Clinical response using Rutherford classification categories
Aikaikkuna: 12, 24, and 36 months
|
The Rutherford classification is a clinical scale used to categorize the severity of peripheral arterial disease: Category 0 = asymptomatic; Category 1 = mild claudication; Category 2 = moderate claudication; Category 3 = severe claudication; Category 4 = ischemic rest pain; Category 5 = minor tissue loss; Category 6 = severe tissue loss. |
12, 24, and 36 months
|
|
Wound status
Aikaikkuna: 12, 24, and 36 months
|
Defined as healing status of the dominant ischemic wound of the target limb (complete, partial, unchanged, worsening). |
12, 24, and 36 months
|
|
Freedom from major amputation of the target limb
Aikaikkuna: 12 and 24 months
|
Defined as absence of any amputation of the target limb (above ankle). |
12 and 24 months
|
|
Amputation-free survival
Aikaikkuna: Until the end of the follow-up period of 3 years
|
Defined as time between first index procedure and amputation of the target limb, minor (digital, metatarsal), major below the knee or major above the knee (excluding any amputation planned before the index procedure). |
Until the end of the follow-up period of 3 years
|
|
Overall survival
Aikaikkuna: Until the end of the follow-up period of 3 years
|
Defined as the time between the first index procedure and death of any cause. |
Until the end of the follow-up period of 3 years
|
|
Patient-reported health-related quality-of-life
Aikaikkuna: Baseline, Day 0 (day of procedure), 6-, 12-, 24-, 26-months post treatment
|
Measured by Vascular Quality of Life Questionnaire - 6 items (VascuQol-6), which is a short patient-reported outcome measure (PROM), used to assess health-related quality of life in people with PAD. It consists of 6 questions, each scored from 1 to 7, with 1 as the worst possible quality of life and 7 as the best possible quality of life. Higher overall scores reflect better quality of life for patients with PAD. |
Baseline, Day 0 (day of procedure), 6-, 12-, 24-, 26-months post treatment
|
|
Frequency and severity of procedural complications and other adverse events
Aikaikkuna: Within 30 days after the index procedure
|
Grading according to the classification system of the Cardiovascular and Interventional Radiological Society of Europe. |
Within 30 days after the index procedure
|
|
Frequency of major adverse limb events (MALE) and peri-operative death (POD).
Aikaikkuna: 6 months for MALE; Within 30 days after the index procedure for POD
|
MALE include above-ankle amputation in the index limb, major re-intervention on the index limb at 6 months and POD includes perioperative (30-day) mortality. |
6 months for MALE; Within 30 days after the index procedure for POD
|
|
Clinical response using ankle-brachial index (ABI)
Aikaikkuna: 12, 24, and 36 months
|
The ankle-brachial index (ABI) is a non-invasive measure calculated as the ratio of systolic blood pressure at the ankle to systolic blood pressure at the arm. ABI categories commonly used to classify peripheral arterial disease are: >1.40 = non-compressible arteries; 1.00-1.40 = normal; 0.91-0.99 = borderline; 0.41-0.90 = mild to moderate peripheral arterial disease; <0.40 = severe peripheral arterial disease. |
12, 24, and 36 months
|
|
Clinical response using toe pressure
Aikaikkuna: 12, 24, and 36 months
|
The toe pressure test measures distal limb perfusion by recording systolic pressure at the toe. In CLTI patients, toe pressure ≤30 mmHg is commonly used to indicate severe ischemia, while values >30 mmHg suggest better perfusion. |
12, 24, and 36 months
|
|
Clinical response using WIfi (wound, ischemia and foot infection) score
Aikaikkuna: 12, 24, and 36 months
|
The WIfI classification is a staging system used to assess CLTI based on wound extent, ischemia severity, and foot infection. Each component is graded from 0 (none) to 3 (severe). Lower WIfI scores indicate a lower risk of limb loss and a lesser urgency for revascularization, whereas higher scores indicate greater disease severity, higher amputation risk, and greater potential benefit from revascularization. |
12, 24, and 36 months
|
|
Restoration of normal lumen per target lesion
Aikaikkuna: Immediately upon procedure completion
|
Defined as residual stenosis ≤30%, immediately after completion of full planned procedure. |
Immediately upon procedure completion
|
Yhteistyökumppanit ja tutkijat
Yhteistyökumppanit
Tutkijat
- Opintojen puheenjohtaja: Gerd Grözinger, Prof. Dr. med., SLK Kliniken Heilbronn GmbH
- Opintojen puheenjohtaja: Marianne Brodmann, Univ.-Prof. Dr. med., Medizinische Universität Graz
- Opintojen puheenjohtaja: Raghu Lakshminarayan, Dr, Hull University Teaching Hospital
- Opintojen puheenjohtaja: Stefan Müller-Hülsbeck, Prof. Dr. med., DIAKO Krankenhaus gGmBH
Julkaisuja ja hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
- Perifeeristen valtimoiden sairaus
- CLTI
- Infrapopliteaaliset valtimot
- Kriittinen raajaa uhkaava iskemia
- Infrapopliteaalinen valtimotauti
- Esprit BTK Everolimus-Eluting Resorbable Scaffold
- Lääkeaineita vapauttava imeytyvä tukirakenne
- Resorboituva verisuonituki
- Todellisuuden mukainen näyttötutkimus
- Potilaat, joilla on infrapopliteaalinen sairaus
- Kalkkeutuneet ääreisvaltimosairausmuutokset
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- RESCUE
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .